<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR29">
 <label>29.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Assouline</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Culjkovic-Kraljacic</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Bergeron</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Caplan</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Cocolakis</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Lambert</surname>
    <given-names>C</given-names>
   </name>
  </person-group>
  <article-title>A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E</article-title>
  <source>Haematologica</source>
  <year>2015</year>
  <volume>100</volume>
  <issue>1</issue>
  <fpage>e7</fpage>
  <lpage>9</lpage>
  <pub-id pub-id-type="doi">10.3324/haematol.2014.111245</pub-id>
  <?supplied-pmid 25425688?>
  <pub-id pub-id-type="pmid">25425688</pub-id>
 </element-citation>
</ref>
